NANO MRNA Co.,Ltd. (FRA:3NQ)

Market Cap	61.79M
Revenue (ttm)	817.81K
Net Income (ttm)	-4.36M
Shares Out	n/a
EPS (ttm)	-0.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.8350
Previous Close	0.7950
Day's Range	0.8350 - 0.8350
52-Week Range	0.6600 - 1.1500
Beta	n/a
RSI	62.23
Earnings Date	Feb 13, 2026

About NANO MRNA

NANO MRNA Co.,Ltd. researches, develops, produces, and sells pharmaceuticals using micellar nanoparticles technology in Japan. The company’s pipeline products include RUNX1 (mRNA) for the treatment knee osteoarthritis and reduces pain; and NC-6100 PRDM14 (siRNA), which is in phase I clinical trials for the treatment of breast cancer. Its product pipeline also comprises TUG1 (ASO) for glioblastoma multiforme. In addition, it offers cosmetic raw material. The company was formerly known as NanoCarrier Co., Ltd. and changed its name to NANO MRNA Co...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1996
• Employees: 20
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 3NQ

Financial Performance

In 2024, NANO MRNA's revenue was 108.00 million, a decrease of -20.00% compared to the previous year's 135.00 million. Losses were -835.00 million, 7.05% more than in 2023.

Financial numbers in JPY